Kyverna Therapeutics, Inc. (KYTX) AI Stock Price Forecast & Investment Analysis
Latest Analysis Date: August 22, 2025
Kyverna Therapeutics, Inc. (KYTX) - Comprehensive Stock Analysis & Investment Research
Company Overview & Business Profile
Kyverna Therapeutics, Inc. (Stock Symbol: KYTX)
is a leading company in the Life Sciences sector
, specifically operating within the Biological Products, (No Diagnostic Substances) industry.
.
The company has established itself as
an emerging investment opportunity with substantial growth potential.
Financial Performance & Key Metrics Analysis
Market Capitalization: $166 million - Classified as a
small-cap investment offering high growth potential.
Advanced AI Stock Prediction & Price Target Analysis
🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Kyverna Therapeutics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.
Market Position & Competitive Advantage Analysis
Kyverna Therapeutics, Inc. strategically competes in the highly dynamic
Biological Products, (No Diagnostic Substances) marketplace,
representing an emerging small-cap investment with substantial growth potential and market disruption capabilities
.
.
Kyverna Therapeutics, Inc. Stock Price Chart and Technical Analysis
Loading chart data...
Loading Kyverna Therapeutics, Inc. interactive price chart and technical analysis...
Deep dive into Kyverna Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.
Understanding Valuation Metrics
What these metrics mean: Valuation metrics help determine if Kyverna Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.
How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.
For Kyverna Therapeutics, Inc.:
P/B Ratio0.90x
Market Cap$166M
EPS$-3.68
Book Value/Share$4.26
Understanding Profitability Metrics
What these metrics mean: These ratios measure how efficiently Kyverna Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.
How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.
For Kyverna Therapeutics, Inc.:
Understanding Financial Health Metrics
What these metrics mean: These ratios assess Kyverna Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.
How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.
For Kyverna Therapeutics, Inc.:
Understanding Cash Flow Metrics
What these metrics mean: Cash flow metrics reveal Kyverna Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.
How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.
For Kyverna Therapeutics, Inc.:
Understanding Operational Efficiency Metrics
What these metrics mean: These ratios measure how effectively Kyverna Therapeutics, Inc. uses its assets and manages working capital.
How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.
For Kyverna Therapeutics, Inc.:
Understanding Financial Statement Data
What these metrics mean: Key figures from Kyverna Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.
How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.
For Kyverna Therapeutics, Inc.:
Income Statement ($ Millions)
Operating Income$-117M
Net Income$-106M
R&D Expense$90M
Balance Sheet Highlights ($ Millions)
Dividend & Shareholder Information
Shares Outstanding43M
Growth Metrics (YoY)
EPS Growth-116.4%
Kyverna Therapeutics, Inc. (KYTX) Fundamental Analysis & Insider Trading Data
(Quarterly Financial Reports)
Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Kyverna Therapeutics, Inc. stock analysis.
Loading fundamental data...
Loading Kyverna Therapeutics, Inc. comprehensive fundamental analysis and insider trading data...
Latest Kyverna Therapeutics, Inc. Stock News & Market Analysis
Breaking news, analyst reports, and market updates affecting Kyverna Therapeutics, Inc. (KYTX) stock price and investment outlook.
KYVERNA THERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX ...
If you suffered a loss in Kyverna Therapeutics, Inc. during the relevant time frame, you have until February 7, 2025 to request that the Court appoint you as lead plaintiff.
RADNOR, PA-- December 27, 2024- The law firm of Kessler Topaz Meltzer& Check, LLP informs investors that a securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. on ...
In the IPO, Kyverna offered 14.5 million shares of common stock at a price of $22.00 per share and Kyverna received net proceeds of approximately $296 million.
--Kyverna Therapeutics, Inc., a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today ...
A look at the shareholders of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) can tell us which group is most powerful. With 40% stake, institutions possess the maximum shares in the company.
Kyverna Therapeutics Inc. raised $319 million in a US initial public offering priced above a marketed range, as drug developers continue to receive a warm welcome from new investors.
Kyverna Therapeutics Inc. rose as much as 59% in early trading after its expanded US initial public offering raised $319 million, as drug developers continue to receive a warm welcome from new ...
Kyverna Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector
Comparative analysis of Kyverna Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.
Frequently Asked Questions - Kyverna Therapeutics, Inc. Stock Forecast
How accurate are Kyverna Therapeutics, Inc. stock predictions?
Our AI model demonstrates 62% historical accuracy for KYTX predictions, based on advanced machine learning algorithms trained on over 10 years of market data.
What factors influence Kyverna Therapeutics, Inc. stock price forecasts?
Is Kyverna Therapeutics, Inc. a good investment in 2025?
Based on our AI analysis, Kyverna Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.
How often are Kyverna Therapeutics, Inc. forecasts updated?
Kyverna Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.
Want More Advanced Kyverna Therapeutics, Inc. Analysis?
Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Kyverna Therapeutics, Inc. stock.
